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Oxidative stressregulating neural functions through cyclic GMP, nitric oxide is emerging as an
endogenous physiological modulator of energy conservation for the brain. Thus, nitric oxide inhibits
cytochrome c oxidase activity in neurones and glia, resulting in down-regulation of mitochondrial energy
production. The subsequent increase in AMP facilitates the activation of 5′-AMP-dependent protein kinase,
which rapidly triggers the activation of 6-phosphofructo-1-kinase – the master regulator of the glycolytic
pathway – and Glut1 and Glut3 — the main glucose transporters in the brain. In addition, nitric oxide
activates glucose-6-phosphate dehydrogenase, the ﬁrst and rate-limiting step of the pentose–phosphate
pathway. Here, we review recent evidences suggesting that nitric oxide exerts a ﬁne control of neuronal
energy metabolism by tuning the balance of glucose-6-phosphate consumption between glycolysis and
pentose–phosphate pathway. This may have important implications for our understanding of the
mechanisms controlling neuronal survival during oxidative stress and bioenergetic crisis.
© 2008 Elsevier B.V. All rights reserved.1. The formation of nitric oxide and peroxynitrite in neural cells
Nitric oxide (NO) is formed by the NO synthase (NOS)-catalyzed
reaction from L-arginine [1] in all brain cells [2]. Constitutive neuronal
NOS (NOS1), which transiently produces NO, can be activated, in a
Ca2+–calmodulin-dependent manner, by the stimulation of pre-
synaptic glutamate receptors. All glial cells in the central nervous
system (astrocytes, microglia and oligodendrocytes), can continuously
produceNO, at approximately 0.5 nmol/106 cells in the steady state [3],
after transcriptional expression of inducible NOS (NOS2), a Ca2+–
calmodulin-independent enzyme. Brain ischemia or septic shock can
promote NOS2 induction in glia in vivo; and lipopolysaccharide –with
or without interferon-γ, tumour necrosis factor-α or interleukin-1ß –
triggers NOS2 induction in cultured glial cells [2]. Thus, while NOS1
releases NO in pulses, NO from transcriptionally-activated NOS2 can; F2,6P2, fructose-2,6-bispho-
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l rights reserved.reach a steady-state level of production. Endothelial NOS (or NOS3) is a
third, Ca2+–calmodulin-dependentNOS isoform that releasesNO in the
brain microvasculature. Since NO is diffusible, NOS3-derived NO
reaches the surrounding smooth muscle cells, where it promotes
soluble guanylyl cyclase (sGC) activation, leading to cyclic GMP-
dependent muscle relaxation and vasodilatation [4]. Thus, NOS3-
mediated vasodilatation is thought to be critically important for
neuronal death/survival decisions in stroke [5]. Neurons also synthe-
size cGMP in response to NO by activation of sGC, an heterodimeric
heme-containing enzyme that is differentially regulated during brain
development by the N-methyl-D-aspartate (NMDA) receptors [6] and
under certain neuroinﬂammatory conditions in glia [7]. The NO-cGMP
signaling cascade is mainly mediated by cGMP-dependent serine/
threonine protein kinases (cGKI or cGKII) [8], which regulate several
physiological functions including hippocampal and cerebellar learning
[9].
By reacting with superoxide anion (O2·−), NO can spontaneously
form peroxynitrite anion (ONOO−) [10]. Being stable in alkaline
solutions, peroxynitrite can be protonated at physiological pH,
decomposing into chemical species with hydroxyl radical (·OH)-like
reactivity and nitrogen dioxide (·NO2); the latter two free radicals
spontaneously form themore stable nitric acid at physiological pH [11].
These reactions have conferred pro-oxidant properties to peroxynitrite,
and are thought to execute some neurotoxic NO-mediated responses
[11,12]. However, this issue has been re-visited [13].
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In activated macrophages, mitochondrial O2 consumption was ﬁrst
found to be down-regulated by NO [14], which could be responsible for
killing of neighboring tumour cells [15]. Later, it was found that the
inhibition of O2 consumption by NO occurred reversibly at the level of
cytochrome c oxidase [16], a ﬁnding that was conﬁrmed in synapto-
somes [17]. Independently, the inhibition of cytochrome c oxidase by
NO in brain mitochondria [18] and by endogenously-released NO in
cultured astrocytes [19] was also reported, suggesting that the NO-
cytochrome c oxidase interaction would be a phenomenon conserved
in brain cells. Thus, exogenous NO rapidly and reversibly inhibits
neuronal energy production in hippocampal neurones [20], and
cytochrome c oxidase, which is thought to be an endogenous marker
for neuronal activity [21], co-localizes with NOS1 and NMDA receptors
[22]. These observations strongly suggest that NO might be an
endogenous regulator of cytochrome c oxidase, and hence mitochon-
drial energy conservation, in vivo. Data in support of this hypothesis are
the fact that cortical neurones incubated in the presence of glutamate at
100 µM, i.e. a concentration compatible with the estimated amino acid
levelswithin the synaptic cleft (ranging from2 to 1000 µM) [23], trigger
a rapid (5min) and reversible inhibition ofmitochondrial ATP synthesis
in a NOS and NMDA receptor-dependent manner [24]. Finally, it has
recently beendescribed that hypoxia synergizeswithNOS1-derivedNO
at triggering mitochondrial inner membrane depolarization and
neuronal death through a cytochrome c oxidase-mediated mechanism
[25]. Taken together, those studies strongly suggest that the mitochon-
dria bioenergetics in neural cells represent an important physiological
and pathophysiological target of NO [26].
3. Neurones are more vulnerable than astrocytes to nitric oxide
and peroxynitrite-mediated damage
Soon after the elucidation of the biological actions of NO [27,28], its
role in NMDA-mediated neurotoxicity was reported [29], not without
some controversy [30]. Neuronal cell culture conditions, different cell
types distribution, amongst other possible reasons might account for
such a discrepancy. For instance, glial cells are more resistant than
neurones to NO or peroxynitrite [31], and different antioxidant defence
systems, such as that of glutathione, superoxide dismutase, catalase or
glutathione peroxidase activities [32,33] account for the different cell
vulnerability. It is therefore well established that incubation of neurons
and astrocytes with identical concentrations of peroxynitrite [31], or
H2O2 [34], glutathione is depleted in neurones, but not in astrocytes.
Moreover, inhibitng glutamate-cysteine ligase – GCL, the enzyme
that catalyzes the rate-limiting step of glutathione biosynthesis – with
L-buthionine sulfoximine renders astrocytes with less glutathione
concentration that are vulnerable to peroxynitrite [35]. In neurons,
knockdown of either the catalytic or the modulatory subunit of GCL
by a small interfering RNA approach triggers spontaneous apoptotic
neuronal death, rendering neurons more vulnerable to NO and NMDA-
receptor over-activation [36]. Altogether, these observations are
compatible with the idea that the glutathione status is an important
contributing factor that governs thedifferent vulnerabilityof neural cells
to NO-mediated toxicity. However, other possible mechanisms, such as
the lower sensitivity of astrocytes –when compared with neurons – to
increase intracellular Ca2+ upon NMDA-receptor over-activation may
also contribute to such different vulnerability against NO and or
peroxynitrite.Moreover, the abilities of cells to regulate the conservation
of energy may also operate as an additional mechanism of survival.
4. Modulation of the glycolytic pathway by nitric oxide: impact on
cell survival
For long, it has been known that, in cultured astrocytes, NO can up-
regulate the rate of glucose consumption and lactate production,suggesting glycolysis activation, a phenomenon that is possibly a
consequence of the NO-mediated mitochondrial inhibition [19].
However, it is surprising that, in contrast to astrocytes, neurones do
not display increased glycolytic rate upon mitochondrial inhibition
with antimycin [37] or peroxynitrite [31], and leads these neuronal
cells to cell death. This observation has been conﬁrmed by inhibiting,
using controlled NO concentrations (~1.5 µM, as released from the
NO-donor, DETA NONOate), the rate of mitochondrial O2 consumption
at a similar degree (~85%) in both neurones and astrocytes; again, only
astrocytes respond by activating, very rapidly (within few minutes),
the glycolytic pathway [38]. Interestingly, the increased glycolytic rate
in astrocytes served to preserve cells from ATP depletion and cell
death, possibly because glycolytic ATP served to drive the reverse
activity of ATP synthase in order to maintain the mitochondrial
membrane potential [38]. By contrast, such treatment promoted
neuronal ATP depletion and apoptotic cell death [38]. Together, these
set of correlations suggest that the inhibition of mitochondrial
respiration by NO would up-regulate the glycolytic ﬂux in astrocytes
to prevent the depletion of ATP; in contrast, neurones do not seem to
express an adequate system to respond similarly. It is noteworthy that
in several neurodegenerative diseases, such as Alzheimer or Hunting-
ton, decreased neuronal glycolytic activity has been observed in
neurons of the degenerating area [39,40]. It is therefore of high
interest to understand the mechanism(s) responsible for the differ-
ential glycolytic response of astrocytes and neurons upon NO-
mediated mitochondrial inhibition.
5. 6-Phosphofructo-1-kinase (Pfk1) as the target in nitric
oxide-mediated glycolysis up-regulation
ATP is considered to be a feed-back allosteric inhibitor of Pkf1, key
rate-limiting step in the glycolytic pathway [41]. Accordingly, formany
years it has been considered that the decrease in cytosolic ATP
concentrations that follows mitochondrial inhibition would stop Pfk1
inhibition, thus causing a rapid activation of glycolysis [41]. However,
such a simple explanation does not seem to be of physiological
relevance in view of two important contributions, i.e. that ATP-
mediated inhibition of Pfk1 is reverted by increasing the amount of the
enzyme at physiological levels [42], and the discovery of fructose-2,6-
bisphosphate (F2,6P2) as the most potent physiological allosteric
activator of Pfk1 [43] (see below). Indeed, inhibition of mitochondrial
ATP synthesis with NO (and potassium cyanide or oligomycin) triggers
a rapid Pfk1 activation in the intact, but not disrupted astrocytes [44].
This indicates that the effect of NO on Pfk1 does require an endogenous
allosteric activator, such as F2,6P2. In fact, NO promotes a rapid and
persistent accumulation of F2,6P2 concentrations in astrocytes, but not
in neurones [44]. Furthermore, the inhibition of 6-phosphofructo-2-
kinase/fructose-2,6-bisphosphatase (Pfkfb), i.e. the bifunctional
enzyme responsible for F2,6P2 formation and degradation, using a
RNA interference strategy against the isoform 3 (Pfkfb3), rendered
astrocytes not being able to increase F2,6P2 levels, activate Pfk1 and
up-regulate the glycolytic rate [44]. It should be mentioned that Pfkfb
is expressed under four isoforms (Pfkfb1-4), of which Pfkfb3, the one
having the highest kinase/bisphosphatase activity ratio [45], is the
most abundant in rat cultured astrocytes [44]. Accordingly, Pfkfb3
mediates Pfk1 activation and glycolytic stimulation by NO [44], at least
in astrocytes.
The involvement of other glycolytic enzymes, such as hexokinase
(s), pyruvate kinase and glyceraldehy-3-phosphate dehydrogenase
(GADPDH), cannot be disregarded as potential targets of NO-mediated
glycolysis activation. In this context, it should bementioned that it has
been previously shown that GAPDH, a NAD+-requiring enzyme that,
together with phosphoglycerate kinase, is responsible for the
substrate level phosphorylation of ADP in the glycolysis pathway
[41], is inhibited by NO [46,47]. This is an intriguing observation, at
least at the light of the increased glycolytic rate above-mentioned;
Fig. 1. Interactions of nitric oxide with regulatory steps of glycolytic and pentose–
phosphate pathways in neurones and astrocytes. After its uptake by the brain cells
through Glut1 and Glut3 facilitative glucose transporters, hexokinase(s) (HK) mediates
glucose phosphorylation, yielding glucose-6-phosphate (G6P), which plays a pivotal
role as common precursor for the several metabolic glucose-consuming routes.
Glycogen biosynthesis in the brain is mostly conﬁned to astrocytes, where it represents
an important fuel store under conditions of low glucose supply. While G6P metabolism
through glycolysis fuels glucose towards energy production, pentose–phosphate
pathway (PPP) conserves the redox equivalents of G6P as NADPH(H+). The rate-limiting
step in PPP activity is catalyzed by glucose-6-phosphate dehydrogenase (G6PD), which
oxidizes G6P to 6-phosphogluconate (6-PG) (the intermediate lactamase-catalyzed
reaction is omitted for simplicity); next, 6-PG is further oxidized to ribose-5-phosphate
(R5P) by 6-phosphogluconate dehydrogenase (6PGD) (intermediate phosphopentose
isomerase-catalyzed reaction is omitted for simplicity). One of the best regulated steps
of glycolysis is the 6-phosphofructo-1-kinase (Pfk1)-catalyzed reaction, which converts
fructose-6-phosphate (F6P) into fructose-1,6-bisphosphate (F1,6P2). Neurones and
astrocytes respond differentially to the NO-mediated inhibition of mitochondrial
respiration at cytochrome c oxidase. Pfk1 is regulated by fructose-2,6-bisphosphate
(F2,6P2), the most potent positive effector of Pfk1. Thus, F2,6P2 dictates Pfk1 activity and
glycolytic rate. F2,6P2 is formed (and degraded) from F6P by the activity of 6-
phosphofructo-2-kinase/fructose-6-phosphatase (Pfkfb), of which four different iso-
forms have been reported. Of these, isoform 3 (Pfkfb3) expresses the highest kinase to
bisphosphatase ratio, and is the most abundant Pfkfb isoform in brain cells. NO
increases the AMP:ATP ratio, promoting AMPK stimulation and activating F2,6P2
formation by Pfkfb3. Thus, in astrocytes, NO switches the rate of glycolytic on, and
pyruvate conversion into lactate recovers NAD+ in the cytosol for glycolysis to continue.
This can supply sufﬁcient ATP to compensate for themitochondrial membrane potential
(Δψm) – by driving the reverse activity of ATP synthase – and energy deﬁciency. In
contrast to astrocytes, neurones do not respond by activating glycolysis upon NO-
mediated inhibition of mitochondrial respiration, possibly because of the low
expression of Pfkfb3 protein. This may lead to a bioenergetic crisis, compromising
neuronal survival. However, the NO-mediated stimulation of facilitative glucose
transporter – an AMPK-mediated process –, together with the effect of NO-derived
peroxynitrite at up-regulating G6PD, support G6P oxidation through the PPP. Thus,
NADPH(H+) regeneration favours GSH regeneration from GSSG, hence contributing to
neuronal protection against oxidative damage. PGI, phosphoglucose isomerase. (The
stoichiometry of the biochemical reactions has been omitted).
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necessary to limit glycolytic ﬂux [48]. Nevertheless, GAPDH-mediated
glycolysis enhancement has recently been reported to cooperate with
autophagic mechanisms in preventing caspase-independent cell
death [49], further supporting the notion that glycolysis activation is
an important survival pathway.
6. Nitric oxide activates 5′-AMP-dependent protein kinase: a
molecular switch in the rapid up-regulation of glycolysis
Using speciﬁc cyclic GMP inhibitors and sGC activators, it has been
shown that the mechanism whereby NO up-regulates glycolysis is
cyclic GMP-independent [44]. In view of the impact of NO on
bioenergetics by inhibiting cytochrome c oxidase, the potential role
for the cell energy sensor, AMPK, as a mediator of the NO-triggered
glycolytic activationwas examined. AMPK is activated by AMPK kinase
(Lkb1)-mediated phosphorylation of its α1-subunit (at Thr-172) in
response to increased AMP:ATP ratio [50]. Once active, AMPK
phosphorylates several substrates, which modify the ﬂux through
certain metabolic routes as an attempt to conserve the cell energy
balance [51]. Results from our laboratory have shown that, upon
inhibition of mitochondrial respiration by NO, the AMP:ATP ratio
increases by ~5-fold [52], and also that AMPK-α1 subunit Thr172
phosphorylation can occur in astrocytes [44,52]. Interestingly,
previous observations have shown that, at least in response to in
vivo heart ischemia, AMPK phosphorylates and activates Pfkfb2 [53].
Thus, the possibility that Pfkfb3 activation in astrocytes in response to
NO would be mediated by AMPK was explored. Knockdown of AMPK-
α1 by small hairpin RNA rendered, indeed, astrocytes unable to
increase their F2,6P2 concentrations in response to NO treatment, and
having lost the ability to activate Pfk1 activity and glycolytic rate [44].
Together, these observations strongly suggest that NO would rapidly
activate glycolysis indirectly, i.e. through the inhibition of mitochon-
drial respiration. This leads to an increased AMP:ATP ratio, which
synergize with Lkb1 at activating AMPK that in turn would mediate
Pfkfb-triggered F2,6P2 elevations, Pfk1 allosteric activation and
glycolysis up-regulation. Furthermore, to provide a sufﬁcient intra-
cellular glucose availability, NO also stimulates glucose uptake by
promoting rapid translocation of Glut1 and Glut3 glucose transporter
subtypes [52]. This effect has been shown to require AMPK- α1 Thr172
phosphorylation [52], which might promote glucose transporters
phosphorylation and translocation to the plasma membrane. AMPK
would thus play a central role in the coordination of intracellular
glucose supply to astrocytes, which is necessary for the rapid
activation of glycolysis upon mitochondrial inhibition by NO (Fig. 1).
7. The pentose–phosphate pathway: a glucose-consuming
metabolic route essential for neuronal survival
Besides its role at supplying ribose-5-phosphate for nucleic acid
biosynthesis, glucose oxidation through the pentose–phosphate
pathway (PPP) is a key component of the cytosolic NADPH(H+)
regenerating cell machinery [41]. The rate-limiting step in PPP activity
is catalyzed by glucose-6-phosphate dehydrogenase (G6PD), which
oxidizes glucose-6-phosphate into 6-phosphogluconate (6-PG), con-
serving the redox energy (reducing equivalents) as NADPH(H+). Next,
6-PG is further oxidized by 6-phosphogluconate dehydrogenase
(6PGD), which also conserves redox equivalents as NADPH(H+) [41].
In post-mitotic cells such as neurones, most PPP-derived NADPH(H+)
is mainly used as a cofactor for the regenerating pathway of
antioxidant glutathione (GSH), which is reduced from its oxidized
form (GSSG) through a reaction catalyzed by glutathione reductase
[54]. In fact, the antioxidant role of the PPP has been demonstrated in
neurones [55] and in astrocytes [56], in which H2O2 causes consider-
able stimulation of PPP activity eliciting cell protection against H2O2
toxicity. PPP stimulation has also been observed in synaptosomes bymonoamine oxidase activation [57], triggered by a number of
neurotransmitters including catecholamines or dopamine. This
suggests a potential role for PPP in glutathione regeneration at
inhibitory or excitatory synapses [58]. Furthermore, similar results
have been obtained by peroxynitrite, which, at low doses (boli of up to
100 µM), directly triggers a rapid activation of PPP and NADPH
accumulation in both neurones and astrocytes [59] through a
mechanism involving stimulation of G6PD activity [59]. Interestingly,
peroxynitrite can – through such a mechanism – exert transient
(despite full) protection of neurones from oxidative stress-mediated
cell death [59]. Although this preservation of neuronal survival
exerted by peroxynitrite may be in apparent contradiction with the
widely held notion of its neurotoxic effects [11,31], it should be noted
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Examples of this include, e.g., the fact that NO affords cytoprotection
against O2·− [60,61] and H2O2-mediated cytotoxicity [62]. In view that
peroxynitrite is formed by the spontaneous reaction between NO and
O2·− [11], it could be surmised that peroxynitrite is the trigger of such a
protection. This notion is in agreement with the in vivo and in vitro
studies reporting prevention of leukocytes adhesion to endothelium
and myocardial necrosis by H2O2 and ischemia–reperfusion, respec-
tively, due to pretreatment with low doses of peroxynitrite [63]. Thus,
it is conceivable that the up-regulation of PPP triggered by NO and/or
peroxynitrite may serve as an attempt of neurones to compensate for
the glutathione oxidation accompanying oxidative stress.
8. Link between glycolysis and PPP regulation: neuroprotection by
fructose-1,6-bisphosphate (F1,6P2)?
We have described that incubation of post-mitotic cortical
neurones in the presence of excess D-glucose – but not of its inactive
enantiomer, L-glucose – prevents against the apoptotic neuronal death
caused by NMDA-receptor activation – 100 µM glutamate for 5 min –
[64]. Surprisingly, the metabolic fate of such excess D-glucose was not
glycolysis, but PPP activity, whichwas essential to prevent NADPH loss
and to keep glutathione in its reduced form [64]. In fact, the protein
levels of Pfkfb3 – the master regulator of F2,6P2 and, hence, of
glycolysis –, is not detectable in post-mitotic neurons by Western
blotting [44]. This might explain the above-mentioned preference of
neuronal cells to use excess glucose through the PPP, instead of
glycolysis [64]. Furthermore, low Pfkfb3 protein levels may also be a
contributing factor to the well-known neuronal vulnerability against
mitochondrial inhibition by NO or ischemia. In support of this notion,
incubation of astrocytes, brain slices or cortical neurones in culture
with exogenous F1,6P2 – the product of Pfk1 activity –, or in vivo
administration of F1,6P2, activates glucose consumption through the
PPP leading to cellular protection against oxidative stress [65–67] or
epileptic convulsion [68]. Despite this is an interesting observation, no
convincing mechanism has been provided so far. Thus, due to its
considerable negative charge and the absence of a known carrier,
exogenously added F1,6P2 very unlikely can enter the cells, and the
stimulatory effect of F1,6P2 on PPP has been shown not to be due to its
own consumption [67]. Accordingly, the possibility that exogenous
F1,6P2 might trigger a still-unknown signaling pathway causing PPP
activation is an interesting speculation that would require further
research.
In conclusion,we suggest that thebalance between glucose oxidation
through glycolysis and PPP may be an important control point of
neuronal survival during bioenergetic crises and oxidative stress.
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